Videos

CancerNetwork® sat down with Robert A. Figlin, MD, at the 2021 ASCO Annual Meeting to discuss the results of the KEYNOTE-564 trial with adjuvant pembrolizumab in patients with resected clear cell renal cell carcinoma. 

Robert A. Figlin, MD, Spotlights Key Findings With Adjuvant Pembrolizumab in Resected Clear Cell RCC From ASCO 2021

Articles

Individuals with an early-onset colorectal cancer diagnosis had a survival benefit versus those at later ages, especially for patients younger than 50 years old. 

Early-Onset Colorectal Study Shows Better Overall Survival for Patients Under 50

Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.

Pembrolizumab Combo Significantly Improved Survival for Persistent, Recurrent, or Metastatic Cervical Cancer

Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.

Saad Z. Usmani, MD, MBA, FACP, Details the Safety Profile for CARTITUDE-1 Trial

Podcasts

CancerNetwork® dissects an article from the journal ONCOLOGY® focusing on academic and community molecular profiling practices for patients with pancreatic adenocarcinoma.

Oncology Peer Review On-The-Go: Molecular Profiling Practices in Pancreatic Adenocarcinoma

All patients with chronic lymphocytic leukemia who were treated with zanubrutinib in the relapsed/refractory setting showed impressive responses. 


Patients With R/R CLL Have Promising Efficacy Outcomes With Zanubrutinib

Targovax announced the FDA granted fast track designation to its investigational agent ONCOS-102 for PD-1–refractory advanced melanoma. 

FDA Grants Fast Track Designation to ONCOS-102 for Treatment of Advanced Melanoma

Bayer seeks FDA approval for its agent copanlisib in combination with rituximab for the treatment of patients with indolent non-Hodgkin lymphoma. 

Application for Copanlisib/Rituximab Combo Submitted to FDA for Indolent NHL

At the 2021 ASCO Annual Meeting, Stephen Liu, MD, discussed the important of findings from the ARROW trial of pralsetinib in patients with RET-altered non–small cell lung cancer. 

Stephen Liu, MD, on How Targeted Therapy Results in Significant Efficacy for RET-Altered Tumors

During the 2021 ASCO Annual Meeting, Suresh S. Ramalingam, MD, looked forward to how trials regarding adjuvant therapy for early-stage non–small cell lung cancer are poised to change the treatment paradigm in this setting. 

All News